Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma

  title={Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma},
  author={Yu Cao and M. Roth and Sajida Piperdi and Kristofer Montoya and R. Sowers and P. Rao and D. Geller and P. Houghton and E. Kolb and J. Gill and R. Gorlick},
  journal={PLoS ONE},
  • Yu Cao, M. Roth, +8 authors R. Gorlick
  • Published 2014
  • Biology, Medicine
  • PLoS ONE
  • Background Survival outcomes for patients with osteosarcoma (OS) have remained stagnant over the past three decades. Insulin-like growth factor 1 receptor (IGF1R) is over-expressed in a number of malignancies, and anti-IGF1R antibodies have and are currently being studied in clinical trials. Understanding the molecular aberrations which result in increased tumor response to anti-IGF1R therapy could allow for the selection of patients most likely to benefit from IGF1R targeted therapy. Methods… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Targeting IGF1R pathway in cancer with microRNAs: How close are we?
    • 5


    Publications referenced by this paper.
    Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.
    • 98
    • PDF
    Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy
    • 112
    • PDF
    Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy
    • 85
    Targeting the insulin-like growth factor-1 receptor in human cancer
    • 50
    • PDF
    Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
    • 144
    • Highly Influential
    • PDF
    The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.
    • 791
    • PDF